Hi [[ session.user.profile.firstName ]]

Forensic Science

  • Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
  • Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
  • Key topics to be discussed during the webinar:

    1)The paradox in Pharma
    2)HCPs expectations and behaviours
    3)Pharma Digital Maturity
    4)The Orchestrator rep
    5)How to implement?
  • The new EPA METHOD 325 for sampling Volatile Organic Compounds from Fugitive and Area Sources was promulgated in September of 2015. The petroleum refineries have 2 years to comply with the new ruling. Benzene emissions are the focus of the new ruling, but other VOC’s can be monitored using the same sampling tube. The air samples are collected using thermal desorption tubes that are deployed along fenceline of the property and remain deployed for 14 days. The samples are collected passively, without the using of an air sampling pump. After sampling the diffusive endcap is replaced with a metal storage cap and sent to a laboratory where they’re analyzed by thermal desorption gas chromatography. This is the first of a two series presentation that focuses on the analysis side of the workflow. It provides users the steps required to comply with the new EPA fence line regulations and what is needed to optimize the method for high sample throughput. Refineries and testing laboratories will benefit by gaining valuable information on the optimum techniques to perform this method and what it takes to comply. An introduction to the theory and operation of thermal desorption will also be included.
  • According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

    As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous. As important as what we are saying and where these conversations are taking place may be, it is only part of the conundrum. Developing, maintaining and managing content is a continuous challenge, made all the more taxing not only by strict internal deadlines but the cultural, linguistic and regulatory challenges that go hand in hand with managing global communications.

    Working with our expert partner SDL , we present a live webinar which will deliver insight and guidance on this topic, look in depth at one of the more traditional areas of patient liaison – trial recruitment – and bring you advice from the ‘frontline’ on what works in tackling these content challenges.

    On this latest live webinar, we’ll be discussing:
    •How to develop patient-centric recruitment content that REALLY communicates
    •Best practices of how to handle the linguistic, cultural and regulatory challenges often faced with creating multilingual patient-centric content
    •How simple content management best practices can help you become more patient centric with your content
    •Recent case studies: we’ll be discussing recent successes of global pharmaceutical businesses that have optimised and streamlined recruitment processes with relevant, accurate content development in the right language.
  • •Are you looking to deliver your research within Europe?
    •Do you need multiple, reliable sites and experienced investigators?
    •Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed with the Department of Health’s investment in the clinical research network infrastructure in the UK.

    Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we can help.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Dr Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for running clinical research studies.

    You can discover:
    •How much the UK’s market volume of commercial contract research has grown and how we recruited over 34,000 patients to commercial clinical trials in 2014/15
    •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    •The free feasibility service run by the NIHR CRN
    •How to gain access to our experienced clinical experts
    •How we are keeping clinical research in the public eye
    •How the UK is sharpening its competitive edge by achieving more key first global patients

    The NIHR CRN is exhibiting at the BioPharma Asia Convention 2016, visit stand B19 from 22-24 March to find out more about what we do to support clinical research and how we can help you deliver your studies in the UK.